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ABSTRACT
Eosinophilic oesophagitis (EoE) is an inﬂammatory
disorder of the oesophagus which has become
increasingly recognised over recent years, although it
remains underdiagnosed in many centres. It is
characterised histologically by a signiﬁcant eosinophilic
inﬁltration of the oesophageal mucosa (>15 eosinophils
per high powered ﬁeld), and clinically with features of
oesophageal dysfunction such a dysphagia, food
impaction, and proton pump inhibitor (PPI) resistant
dyspepsia. Fibrosis and oesophageal remodelling may
occur and lead to oesophageal strictures. An allergic
predisposition is common in the EoE population, which
appears to be primarily food antigen driven in children
and aeroallergen driven in adults. Evidence suggests that
the pathogenesis of EoE is due to a dysregulated
immunological response to an environmental allergen,
resulting in a T helper type 2 (Th2) inﬂammatory disease
and remodelling of the oesophagus in genetically
susceptible individuals. Allergen elimination and anti-
inﬂammatory therapy with corticosteroids are currently
the mainstay of treatment; however, an increasing
number of studies are now focused on targeting
different stages in the disease pathogenesis. A greater
understanding of the underlying mechanisms resulting in
EoE will allow us to improve the therapeutic options
available.
INTRODUCTION
Eosinophilic oesophagitis (EoE) is an inﬂammatory
disorder of the oesophagus which has become
increasingly recognised over recent years. The car-
dinal feature of this disease is a signiﬁcant inﬁltra-
tion of eosinophils into the epithelial layer of the
oesophagus (ﬁgure 1). The resulting oesophageal
inﬂammation is accompanied by basal layer hyper-
plasia and dilated intracellular spaces with
progression to lamina propria ﬁbrosis over time,
resulting in narrowing of the oesophagus and stric-
ture formation (see companion article by Kumar
et al)1. EoE is associated with considerable morbid-
ity, and symptoms of dysphagia and food impaction
are common. In rare cases rupture of the oesopha-
gus may occur. Despite the signiﬁcant impact on
quality of life, EoE is not associated with an
increased mortality and there is no evidence to
suggest progression to oesophageal cancer.2 This
paper will describe the epidemiology, clinical pres-
entation, diagnosis, and pathophysiology of EoE.
The article by Kumar et al1 will address the investi-
gations and management of EoE.
EPIDEMIOLOGY
EoE was ﬁrst described in 1978,3 but it was not
until 1993 that it was acknowledged as a distinct
clinicopathological entity separate from other
gastrointestinal disorders in which an oesophageal
eosinophilia is observed (box 1).4 EoE is now
recognised in up to 1 in 2500 individuals5 6 with a
prevalence in some centres as high as 15% of
patients presenting with dysphagia to endoscopy
units.7 8 A signiﬁcant increase in the number of
cases has been reported in recent years, with one
study quoting an incidence rise of 4.4–7.4 cases per
100 000 individuals during the period 2005–
2011.5 Whether this observation is due to a true
increase in incidence or improved recognition and
diagnosis remains under debate, but a study by
Hruz et al5 suggests that the incidence is indeed
rising.
The onset of EoE has two peaks, one in child-
hood and the second in the third to fourth decade,
although it may present at any age. There is a male
preponderance, with a male:female ratio of 3:1.9
Figure 1 Histology images of oesophageal epithelial eosinophilia. (A) Squamous mucosa showing basal cell
hyperplasia, elongation of papillae, and numerous eosinophils in the epithelium (haematoxylin and eosin ×100).
(B) Eosinophils in squamous epithelium (arrowhead, >30/high powered ﬁeld). Detail upper right corner: eosinophilic
micro abscess (arrow head, H&E ×400).
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A recent study indicated that African American males may
present with a more aggressive form of EoE earlier than
Caucasians10; however, further studies are necessary to support
this observation and investigate whether the increased prevalence
in males and earlier presentation in African Americans is due to
the pathogenesis of EoE or is related to social or environmental
factors. The current consensus is that there is inconclusive evi-
dence for signiﬁcant socioeconomic, geographical, and/or ethnic
variations.11 12 A seasonal variation is well documented, with
exacerbations and an increased number of new diagnoses of EoE
in the spring (33%) compared with winter (16%), which would
support an environmental or allergen association.11 13
CLINICAL PRESENTATION AND DIAGNOSIS
EoE has been deﬁned as ‘a chronic, immune-antigen-mediated
oesophageal disease characterised clinically by symptoms of
oesophageal dysfunction and histologically by eosinophil-
predominant inﬂammation’ (updated consensus on EoE,
2011).12 The following section will detail the clinical, endo-
scopic, and histological features of EoE.
Clinical features and assessment for allergy
The clinical presentation of EoE varies according to the age of
the patient and the severity of the disease (box 2). In children,
failure to thrive, choking, regurgitation or vomiting after eating
or food refusal is seen.14 Adolescents and adults classically
present with retrosternal discomfort, dysphagia to solids
(70%),9 food bolus impaction (33–54%),15 and intractable dys-
pepsia (38%) which is typically not, or only partially, responsive
to proton pump inhibitors (PPIs). Patients may develop abnor-
mal eating habits to compensate for symptoms, such as eating
small pieces of food (taking little bites, cutting up food into
manageable pieces), chewing excessively, avoiding foods which
are likely to be difﬁcult to swallow (ie, pieces of meat), eating
only a soft diet or softening food with sauces and ﬂuid, or
vomiting after eating. Symptoms are most frequently chronic
and may be intermittent; however, it is not uncommon for
patients to present following a short history or even an acute
event, especially if food impaction is the predominant feature. A
rare but well recognised complication of EoE in adults and chil-
dren is spontaneous oesophageal perforation. A total of 19 cases
of perforation had occurred worldwide by 2011; seven needed
surgical intervention but none was fatal.12 16 17
Up to three quarters of patients may have a personal or
family history of allergy—allergic rhinoconjunctivitis, eczema,
and asthma.18–20 Approximately 50% of patients have periph-
eral eosinophilia (>300–350/mm2)12 or increased levels of
serum IgE,21 22 and 75% have a positive skin prick test to at
least one food allergen—most commonly dairy, eggs, peanuts,
ﬁsh, wheat, soy—or aeroallergens such as dust mite, pollen, and
grass.23 In general, children with EoE tend to have a concomi-
tant allergy to foods, and adults to aeroallergens. This observed
difference in allergen sensitivity between adults and children is
consistent with the ‘allergic or atopic march hypothesis’14
whereby the atopic phenotype presents early in life as skin
rashes (eg, eczema) secondary to food allergens, and progresses
with age to upper and lower respiratory tract conditions such as
allergic rhinitis and asthma, with a reaction-switch to airborne
allergens.24 25 The importance of taking a thorough allergy
history in patients with suspected EoE is highlighted by the
ﬁnding that elimination of common food allergens has been
shown to be of beneﬁt to a proportion of adults26 and chil-
dren27 with EoE. Sufﬁcient evidence is not available to support
routine allergy testing in all patients with EoE, and it is gener-
ally agreed that these tests should be reserved for individuals in
whom the history suggests a food allergen trigger (see article by
Kumar et al)1. It is important here to note that the presence of
allergy in a patient with dysphagia is not diagnostic of EoE and
may be a coincidental ﬁnding.
It is impossible to diagnose EoE on clinical history alone, and
the examination is usually unremarkable—in particular, there
are no identiﬁed oral pharyngeal manifestations. Many other
oesophageal disorders, including gastro-oesophageal reﬂex
disease (GORD), achalasia, and oesophageal cancer, can present
in a similar manner and must be excluded. The diagnosis of
EoE is made histologically from oesophageal biopsies taken
during endoscopy (see box 1 in article by Kumar et al1 for a
complete list of diagnostic criteria for EoE).
Endoscopic features of EoE
Endoscopy is an essential tool to aid in the diagnosis of EoE.
Although the upper gastrointestinal tract of patients with EoE
often look macroscopically normal at endoscopy,28 endoscopic
signs associated with EoE are well documented and a recent
grading system has been validated to score the endoscopic
assessment29 (see table 1 in this article and endoscopic views in
Kumar et al1). Features include a narrow calibre oesophagus
(9%), which may be characterless (41%) or display longitudinal
ridges/furrows (48%), ﬁxed concentric ‘corrugated’ rings/tra-
chealisation (44%) giving the impression of a trachea, strictures
Box 2 Clinical symptoms of eosinophilic oesophagitis in
paediatric and adult patients
Paediatrics
Failure to thrive
Vomiting/regurgitation
Choking
Food refusal
Adults
Dysphagia
Food impaction
Vomiting
Intractable dyspepsia; un/partially responsive to proton pump
inhibitor (PPI)
Box 1 Diseases other that eosinophilic oesophagitis
associated with an oesophageal eosinophilia
Gastro-oesophageal reﬂux disease (GORD)
Proton pump inhibitor (PPI) responsive oesophageal eosinophilia
Eosinophilic gastrointestinal diseases not isolated to the
oesophagus
Crohn’s disease
Coeliac diseases
Atopic disorders
Infection
Hypereosinophilic syndrome
Drug hypersensitivity
Churg-Strauss syndrome and other vasculitides
Graft versus host disease
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(21–40%), Schatzki rings, linear superﬁcial mucosal tears and
‘crepe paper’ effect due to mucosal fragility (59%), and eosino-
philic abscesses (white speckled exudates, 1–2 mm in diameter,
that resemble oesophageal candidiasis) (27%).30 Adults generally
present with more subepithelial ﬁbrosis and oesophageal nar-
rowing than children, and ﬁbrosis increases over time.2 14
Although endoscopy is vital for the diagnosis of EoE, none of
above mentioned ﬁndings is pathognomonic.
Histological features of EoE
Clinical assessment and endoscopic ﬁndings may support a diag-
nosis of EoE, but oesophageal biopsy and histological analysis
of tissue sections are required for the deﬁnitive diagnosis. In
practice the diagnosis of EoE may be missed as oesophageal
biopsies are not routinely carried out unless the indication is
clear, the clinical suspicion is high, or they are particularly
requested by the referring doctor. At least 2–4 biopsies are
recommended, taken from both the distal and proximal
oesophagus,14 although some authors have shown that up to 5–
6 biopsies are required for >99.9% sensitivity.27 A deﬁnitive
diagnosis is made if >15 eosinophils in at least one high
powered ﬁeld (hpf) are seen (ﬁgure 1) and this eosinophilia is
isolated to the oesophagus (ie, not present in gastric and duo-
denal biopsies). Eosinophils stain brightly red with haematoxylin
and eosin stain (ﬁgure 1). They may be found in clusters called
micro abscesses (see inset, ﬁgure 1B) and can be found in the
squamous oesophageal epithelium or deeper oesophageal tissue
layers.
Other diseases, in particular GORD, can be associated with
oesophageal eosinophilia (box 1), and should be excluded,
although it is rare for oesophageal eosinophil levels in these
conditions to exceed 10/hpf. Ideally patients with dyspepsia
should have an 8 week empirical trial of a PPI and/or pH
studies, to exclude GORD and PPI responsive oesophageal
eosinophilia, before reporting a histological diagnosis of EoE
(see Kumar et al)1. If, however, dysphagia is the presenting com-
plaint, patients should proceed directly to endoscopy in order
to exclude a more sinister cause such as oesophageal tumour/
ulceration.
The only marker currently universally accepted to diagnose
EoE is the ‘eosinophil count’ in oesophageal biopsies.12 In a few
cases, however, patients with EoE may have a strong clinical
picture of EoE with <15 eosinophils/hpf but have other histo-
logical features indicative of eosinophilic inﬂammation (table 1).
Markers such as lamina propria ﬁbrosis (determined by tri-
chrome staining) and basal zone hyperplasia (deﬁned as a per-
centage of oesophageal epithelial height; moderate 51–75% or
severe >75%) have been reported to be more prevalent in
adults and children with EoE than in individuals with GORD,
and can be used to assess for EoE in conjunction with the
eosinophil counts (box 3).31 32 Furthermore, some studies have
reported increased numbers of mast cells and immunoglobulin
E (IgE) positive cells,33 indicating an allergic-type process in the
mucosa that differentiates EoE from GORD. Table 2 contains a
list of histological markers which differentiate EoE from
GORD. The contribution of these markers to the pathology of
EoE is discussed further in the pathophysiology section. It is
important to note that immunosuppressive medication (in par-
ticular steroids) taken at the time of endoscopy may alter the
Box 3 Oesophageal histological features of eosinophilic
oesophagitis
>15 eosinophils per high powered ﬁeld
Micro abscesses
Surface layering eosinophils
Extracellular eosinophil granules
Basal layer hyperplasia
Dilated intracellular spaces
Lamina propria ﬁbrosis
Table 1 Endoscopic features of eosinophilic oesophagitis, classification and grading
Grade 0 Grade 1 Grade 2 Grade 3
Major features
Oedema (decreased vascular markings,
mucosal pallor)
Absent; distinct
vascularity
present
Loss of clarity or absence of
vascular markings
Fixed rings (concentric rings, corrugated
oesophagus, corrugated rings, ringed
oesophagus, trachealisation)
None Mild—subtle
circumferential ridges
Moderate—distinct rings that do not
impair passage of a standard diagnostic
adult endoscope (outer diameter 8–9.5
mm)
Severe—distinct rings that
do not permit passage of a
diagnostic endoscope
Exudates (white spots, plaques) None Mild—lesions involving
<10% of the oesophageal
surface area
Severe—lesions involving >10% of the
oesophageal surface area
Furrows (vertical lines, longitudinal furrows) Absent Present
Stricture Absent Present (specify estimated
luminal diameter)
Minor features
Crepe paper oesophagus (mucosal fragility or
laceration upon passage of diagnostic
endoscope but not after oesophageal
dilation)
Absent Present
Narrow calibre oesophagus (reduced luminal
diameter of the majority of the tubular
oesophagus)
Absent Present
Adapted from Hirano et al, 2013.29
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immune cells resident in the biopsy sections and lead to a false
negative result when assessing histologically for EoE.
Pathophysiology of EoE
The aberrant processes which trigger and maintain an increased
inﬁltration of eosinophils and other inﬂammatory cells to the
oesophageal epithelium, and the subsequent T helper type 2
(Th2) inﬂammatory cascade seen in EoE, are not completely
understood (ﬁgure 2). Both clinical and histological features
support a role for allergens in the onset and/or maintenance of
the disease. Recent advances in technologies have helped to
improve our understanding of the pathophysiology of EoE. In
particular, genome-wide analysis studies (GWAS) and mRNA
proﬁling have highlighted candidate genes which may provide
an insight into the mechanism of the disease development34 35—
EoE has been associated with a region on chromosome 5q22 in
a paediatric cohort, and the gene for thymic stromal lympho-
poietin (TSLP), whose protein product is found overexpressed
in atopic disease, is localised to this region.2 3 The following
section will discuss our current understanding of the patho-
logical processes involved in EoE and the evidence supporting
the role of each in the pathophysiology of the disease.
Role of allergens
EoE is strongly associated with allergy. Most patients (70%)
with EoE are found to react to either airborne or food aller-
gens.36 Patients with EoE, who are negative to allergen testing,
also have classic cellular markers of allergy in the oesophagus;
eosinophils, IgE bearing mast cells, and Th2 lymphocytes are
prominent in the oesophagus of EoE patients (see the histology
section and ﬁgure 2).37 Furthermore a wealth of literature has
documented the beneﬁt of allergen elimination through strict
exclusion diets, particularly in children with EoE, which
strongly supports the role of allergy in EoE. Almost complete
resolution of both clinical and histological abnormalities has
been described following exclusion diets38 and a reversal of
oesophageal ﬁbrosis has even been demonstrated in some
studies.27 39 The results in adults are less conclusive, perhaps as
the culprit is more likely to be an aeroallergen, rather than
food.
Th2 type inﬂammation
EoE has been described as an ‘allergen induced disorder’ with a
Th2 type inﬂammatory response. Such a response is
Figure 2 Mechanism of eosinophilic oesophagitis (EoE). Simpliﬁed
diagram showing epithelial and immune cells in the oesophageal
mucosa during EoE. The mucosa is subdivided into a stratiﬁed
epithelial layer (Ep), lamina propria (LP) and the smooth muscle layer,
mucosa muscularis (MM). Inﬂammatory cells inﬁltrating the epithelial
layer are eosinophils (Eos, bilobar nuclei, red intracellular granules),
and mast cells (MC with blue histamine containing granules).
Eosinophils release granules (red stain). B cells (Bc), T cells (Tc) and
dendritic cells (Dc) are present in the LP (the cells have been reported
to be present in Ep and MM as well). T cells release IL-13 which
induces eotaxin-3 production by epithelial cells. Eotaxin-3 is a speciﬁc
chemoattractant for eosinophils attracting the cells from the peripheral
blood. T helper type 2 (Th2) lymphocytes release IL-4 inducing an
antibody isotype switch to IgE isotype in B cells. IgE binds to mucosal
resident MC’s facilitating granule release. Th2 lymphocyte derived IL-5
promotes survival of eosinophils. The epithelium produces thymic
stromal lymphopoietin (TSLP) and stimulates Dc’s to present allergens
for Th2 Lymphocytes. Whitish exudates are present at the epithelium
surface due to accumulation of eosinophils. Medications such as proton
pump inhibitors (PPIs) may act in an anti-inﬂammatory capacity
through inhibition of the allergy associated transcription factor signal
transducer of activator of transcription 6 (STAT-6) or by altering
epithelial permeability. Medications such as antibiotics may additionally
promote EoE by skewing the immune response from a Th1 to Th2
type. Transforming growth factor β (TGF-β) released by epithelial cells,
MC, and Eos induces activation of ﬁbroblasts augmenting ﬁbrosis in
the LP and contraction of the mucosa muscularis (MM), the
combination of which may lead to pathological features such as
strictures.
Table 2 Studies that have evaluated histological markers that discriminate eosinophilic oesophagitis from GORD
Eosinophilic oesophagitis GORD Adult/child Correlation Reference
Intraepithelial eosinophils* 55 (±27.5) 6.9 (±9.7) Children p<0.0001 62
MBP† 1479 (±1290) 59 (±103) Adult p<0.001 46
Eotaxin-3† 2219 (±1782) 479 (±777) Adult p=0.01 46
Intraepithelial mast cells* 26.3 (±12.7) 7.8 (±8.9) Children p<0.0001 62
TGF-β positive cells in LP* 126 (61–191) 9 (2−24) Children p=0.002 31
COX-2‡ 0 0.5** Adult p<0.01 69
The table summarises studies that have assessed potential laboratory markers to discriminate eosinophil oesophagitis from GORD.
*Per high powered field
†Maximum staining density, cells/mm2 (±SD)
‡Monoclonal antibody uptake grading.
**Faint stain in basal layer of epithelium.
COX, cyclo-oxygenase; GORD, gastric oesophageal reflex disease; LP, lamina propria; MBP, major basic protein; TGF-β, transforming growth factor β.
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characteristically induced during allergic reactions and by hel-
minthic infections, and this reaction is also present in the
oesophageal mucosa of patients with EoE. The Th2 type inﬂam-
mation is distinguished by T helper and B lymphocytes, mast
cells, eosinophils, and a speciﬁc cytokine proﬁle from stromal
and epithelial cells.40 Th2 lymphocytes produce interleukin 4
(IL-4), IL-13, and IL-5, and the mRNA for these cytokines have
been found upregulated in the oesophagus of EoE
patients.33 35 41
IL-4 inﬂuences B lymphocytes facilitating antibody class
switching to IgE subclass. A recent study demonstrated that the
increased expression of IL-4 seen in EoE patients, unrelated to a
history of other allergies, was associated with a local immuno-
globulin class switching to IgE and IgE production in the
oesophageal mucosa of EoE patients.33 This ﬁnding suggests
that sensitisation and activation of mast cells involving local IgE
may contribute to the pathogenesis of EoE. Unfortunately, a
small trial of EoE using a speciﬁc anti-IgE antibody (omalizu-
mab) did not reduce oesophageal inﬂammation.42 In line with
these ﬁndings, studies using animal models have demonstrated
that antibody-producing B lymphocytes are not necessary for
EoE pathogenesis (see below).43
IL-13 shares a common signal transduction pathway with
IL-4, via the signalling molecule signal transducer of activator of
transcription 6 (STAT-6). When primary oesophageal epithelial
cell cultures were stimulated with IL-13 an RNA transcript
expression proﬁle emerged, similar to that seen in oesophageal
biopsies from humans with EoE. IL-13 stimulates the produc-
tion of the chemokine eotaxin-3, a speciﬁc attractant of eosino-
phils from epithelial cells and from ﬁbroblasts.35 IL-13 also
induces TSLP which is an IL-7-like cytokine associated with
paediatric EoE in GWAS.2 Epithelium derived TSLP stimulates
dendritic cells inducing a Th2 response.44 mRNA for eotaxin-3
and TSLP was found upregulated in oesophageal biopsies from
EoE patients.45 46 These ﬁnding are unlikely to be a conse-
quence of inﬂammation per se as the expression of eotaxin-3 is
not increased in GORD and can be used as a biomarker to dif-
ferentiate EoE from GORD (see table 2 for other markers that
differentiate EoE from GORD).46 Inhibitors of IL-13, such as
the anti-IL-13 antibodies lebrikizumab or QAX576, may be a
potential therapeutic option.47 48 Lebrikizumab has shown
promising effects in patients with asthma and a high Th2
response, and QAX576 is currently under investigation as a
treatment option for EoE.
IL-5, which is induced by IL-13,49 is known to play a signiﬁ-
cant role in eosinophil differentiation and activation, and levels
of IL-5 are signiﬁcantly elevated in oesophageal biopsies of
patients with EoE.50 A number of IL-5 antagonists have subse-
quently been trialled as a treatment for EoE, and studies to date
demonstrate a signiﬁcant reduction in oesophageal eosinophil
numbers and minor improvements in a few parameters of
oesophageal remodelling (table 3). However, the clinical
response to IL-5 antibodies is variable and as such they are not
recommended for routine use at the present time.12
Animal studies provide further support that allergens and
Th2 cytokines play key roles in the pathogenesis of EoE: the
disorder can be induced by allergens in B lymphocyte deﬁcient
mice43 but not T and B lymphocyte deﬁcient mice,51 and the
disease development in murine models has been shown to be
critically dependent on IL-5 and eotaxin.52 Furthermore,
IL-13 have been shown to promote IL-5 dependent oesopha-
geal eosinophilia in mice.53 However, the importance of IL-4
and IL-13 in the pathogenesis of EoE has recently been chal-
lenged53; allergen induced experimental EoE, in contrast to
lung eosinophilia, was not found to be impaired in IL-13 deﬁ-
cient, STAT-6 deﬁcient, or IL-13/IL4 double deﬁcient mice.
Animal models may not, however, truly replicate the disease
processes occurring in humans, which in EoE may result from
Table 3 Trials using anti IL-5 antibody in eosinophilic oesophagitis
Authors Study design Anti IL5 Adult/ Child N Primary objective(s) Outcome(s)
Stein et al74 Case series Mepolizumab 3 infusions Adult 4 Pronounced reduction in blood and
oesophageal eosinophils
Straumann
et al75
Randomised
placebo
controlled
Mepolizumab 2 infusions 750 mg IV
1 week apart. After 2 months
histological non-responders given a
further 2 infusions 1500 mg 1 month
apart
Adults with ≥20 Eos/
hpf)
11 Complete histological
remission (<5 peak
eosinophil number/
hpf)
1. 4 weeks after starting treatment,
54% reduction of mean
oesophageal eosinophils in patients
receiving active therapy compared
with the placebo group (5%)
(p<0.05)
2. Reduced expression of tenascin C
(p=0.033) and TGF-β (p=0.05)
genes associated with oesophageal
remodelling
3. Trend towards clinical improvement
observed after 4 and 13 weeks
Assa’ad
et al76
Randomised
non-placebo
controlled
Mepolizumab monthly infusion 0.55,
2.5, or 10 mg/kg for 3 months
Children with ≥20
Eos/hpf)
59 Histological
improvement
Peak and mean oesophageal
intraepithelial eosinophil counts
decreased significantly (p<0.0001).
Symptoms were not recorded
Spergel
et al77
Randomised
placebo
controlled
Reslizumab, 1, 2 or 3 mg/kg IV
(monthly intervals for 3 months)
Children/ adolescent;
symptom severity
scores > moderate
>24 Eos/hpf
262 Histological and
clinical improvement
1. Peak oesophageal eosinophil counts
significantly reduced in the groups
receiving reslizumab compared with
placebo group (p<0.001)
2. No significant difference between
physician’s global assessment scores
Eos, eosinophils; hpf, high powered field; IV, intravenous; TGF-β, transforming growth factor β.
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a complex interaction between environmental factors and
host.
Eosinophils, mast cells, and ﬁbrosis
Eosinophils are not usually found in the squamous epithelium
lined oesophagus of healthy individuals.54 The presence of the
eosinophil granulocyte in the oesophageal lamina propria is the
hallmark of EoE. But how important is the cell in the aetiology
of the disease?
Intraepithelial eosinophils in oesophageal biopsies from EoE
patients have been shown to be activated, releasing proteins
and entire eosinophil granules correlating with disease activ-
ity.46 55–57 Two of these granule proteins—the major basic
protein (MBP), which can be used to discriminate EoE from
GORD, and the eosinophil cationic protein (ECP)—can both be
used to monitor response to treatment in EoE and in other aller-
gic diseases.46 58 59 The ﬁnding that MBP induces the release of
mediators from mast cells, and ECP increases the secretion of
transforming growth factor β (TGF-β) from ﬁbroblasts,58 60 sup-
ports the suggestion that the presence of oesophageal eosino-
phils in EoE is pathogenic. TGF-β is a cytokine known to
stimulate ﬁbrosis and inﬂuence smooth muscle contractility.61
Elevated levels of TGF-β have been found in EoE biopsies but
not in GORD,31 which may account for, or contribute to, the
pathologic, endoscopic, and histological changes seen in EoE.
Long term removal of TGF-β has been proposed as a regimen
for treatment of tissue ﬁbrosis.61 Increased numbers of mast
cells, which also produce TGF- β, are seen in the oesophagus of
EoE patients but not of GORD patients.62 The number of mast
cells in the oesophagus and the level of degranulation correlate
with severity of disease.63 If left untreated, ﬁbrosis may cause
permanent damage to the oesophagus and potentially lead to
structuring and debilitating dysphagia. Further research is
needed, however, to determine whether all patients with EoE
are at the same risk for tissue remodelling, how long it takes,
and under what circumstances.64
Although the literature suggests eosinophils do play a patho-
genic role in EoE, the clinical trials of medications which reduce
eosinophil numbers have proved disappointing to date—results
have been variable and improvements minimal. It is entirely
conceivable, however, that once the inﬂammatory cascade has
been triggered, removing the causative cell may have a limited
effect.
Role of concomitant medications
A combination of factors, such as concomitant medication or
changes in bacterial ﬂora, may contribute to the aetiology of
EoE, resulting in a dysregulated immune response to an allergen
with pathological consequences. Whether, and how, allergens
penetrate the oesophagus to stimulate the atopic response is an
interesting question. It has been proposed that medications may
affect oesophageal permeability—some may lead or contribute
to a ‘leaky mucosa’ which could allow allergens to penetrate,
while others may exert a protective effect.
Proton pump inhibitors
PPI resistant dyspepsia is a well recognised feature of EoE.
However, some patients do respond positively to PPI treatment,
but why this should occur is not completely understood.65 It
has been proposed that this phenomenon may relate to the
drug’s anti-inﬂammatory properties. The drug may either
inhibit the Th2 associated transcription factor STAT-6, which
has been shown in squamous epithelial cells from EoE
patients,66 or upregulate haem oyxgenase 1.67 An alternative
explanation might be that PPIs reduce acid damage to the
oesophageal epithelium, in undiagnosed GORD, which may
otherwise result in dilated intercellular spaces and increased epi-
thelial permeability. This would allow for allergens to penetrate
and exacerbate the inﬂammatory load, leading to recruitment of
eosinophils to the oesophagus.68
COX-2 inhibitors
The expression of cyclo-oxygenase 2 (COX-2) in epithelial cells
is increased in GORD, but reduced in EoE.69 IL-13, which is
known to down-regulate COX-2 expression, could be respon-
sible for this. Whether attenuated basal levels of COX-2 derived
prostaglandins from epithelial cells or non-steroidal anti-
inﬂammatory drugs (NSAIDs), which are commonly used in the
general population, inﬂuence disease development is not cur-
rently known. Prostaglandin D2 (PGD2) is, however, produced
and released from activated mast cells (ﬁgure 2). By attenuating
the response of PGD2 via antagonism of its receptor CRTH2,
expressed on T lymphocytes, eosinophils and basophils, using
the compound OC000459, a cohort of adults with severe, non-
responsive EoE were found to have an improvement in
symptoms.70
Role of antibiotics
A recent study reported that antibiotic use in the ﬁrst year of
infancy was associated with six times the odds of developing
EoE.71 Incidentally, the usage of antibiotics has been linked to
allergy development in mice.72 Interestingly the presence of
Helicobacter pylori in gastric biopsies is also inversely correlated
with oesophageal eosinophilia.73 There is, however, no evidence
to suggest that patients undergoing antibiotic induced H pylori
eradication are at greater risk for EoE.
In summary, EoE is a polygenic disorder in which a dysregu-
lated environment in the oesophageal mucosa appears to lead to
inﬂammatory cell inﬁltration and disease development in
response to food allergens and aeroallergens (ﬁgure 2). Both
genetic and/or environmental factors appear to inﬂuence the
production of mediators such as TSLP and eotaxin-3 by epithe-
lial and other stromal cells. Eosinophils, Th2 lymphocytes, and
mast cells are recruited to the mucosa. B lymphocytes may
undergo local IgE class switching. Increasing evidence indicates
that environmental factors, in particular medications such as
antibiotics, particularly early in life, could contribute to disease
development and may even account for the increased incidence
of disease observed.
CONCLUSION
EoE has emerged over recent years as an increasingly common
disease in both adults and children, with a signiﬁcant associated
morbidity. However, it still remains underdiagnosed in many
centres. Substantial advances have been made during the last
decades which have contributed to our understanding of EoE. A
greater awareness and insight into the clinical presentation,
pathological processes involved, and triggers of this complex
disease will facilitate improved diagnostic criteria and enhance
our management through earlier diagnosis and introduction of
novel treatments.
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Main messages
▸ The incidence of eosinophilic oesophagitis (EoE) is
increasing.
▸ EoE is characterised clinically by symptoms of dysphagia,
food impaction and proton pump inhibitor resistant
dyspepsia, and histologically by signiﬁcant eosinophilic
inﬁltration of the oesophageal mucosa.
▸ A minimum of 2–4 oesophageal biopsies should be
taken from the proximal and distal oesophagus to
diagnose EoE.
▸ EoE is associated with atopy and a T helper type 2 (Th2)
response. A thorough allergy history must be taken before
testing for food and aeroallergens in EoE patients.
▸ Genome-wide analysis studies (GWAS) have found EoE to be
associated with a region on chromosome 5q22 in a
paediatric cohort. The gene for thymic stromal
lymphopoietin (TSLP) is localised to this region.
Current research questions
▸ Research and development of novel non-invasive biomarkers
in the diagnosis of EoE is needed.
▸ The inﬂuence and effect of environmental inﬂuences and
medication such as proton pump inhibitors and antibiotics
on the incidence of EoE should be studied.
Key references
▸ Rothenberg ME, Spergel JM, Sherrill JD, et al. Common
variants at 5q22 associate with paediatric eosinophilic
esophagitis. Nat Genet 2010;42:289–91. Identiﬁcation
of genome-wide analysis studies (GWAS) locus for EoE.
▸ Hruz P, Straumann A, Bussmann C, et al. Escalating
incidence of eosinophilic esophagitis: a 20-year prospective,
population-based study in Olten County, Switzerland.
J Allergy Clin Immunol 2011;128:1349–1350. A population
based long term study which demonstrates that the
accelerated incidence of EoE seen in recent years represents
a true increase rather than simply an increased awareness
and diagnosis of disease.
▸ Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic
esophagitis: updated consensus recommendations for
children and adults. J Allergy Clin Immunol 2011;128:
3–20. An excellent reference for up to date consensus
recommendations for EoE.
▸ Straumann A, Aceves SS, Blanchard C, et al. Paediatric and
adult eosinophilic esophagitis: similarities and differences.
Allergy 2012;67:477–490. Comprehensive overview of
paediatric and adult EoE.
▸ Straumann A, Bauer M, Fischer B, et al. Idiopathic
eosinophilic esophagitis is associated with a T(H)2-type
allergic inﬂammatory response. J Allergy Clin Immunol
2001;108:954–961. A landmark study; recognition of
EoE as a Th2-type allergic inﬂammatory disease.
Self assessment questions
For self assessment questions please see the companion article
by Kumar et al1.
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